MIRM ▲ +5.3% - Mirum Pharmaceuticals, Inc. $MIRM Mirum Pharmaceuticals: Phase 3 EXPAND Trial of LIVMARLI Meets Primary Endpoint; Shares Rise 6.1% Premarket ? • LIVMARLI significantly improved cholestatic pruritus vs. placebo (p=0.0004) and reduced serum bile acids by 69% vs. placebo (p<0.0001). • Study also achieved statistical significance across all five prespecified secondary endpoints, including in patients with biliary atresia. • Mirum plans a U.S. sNDA submission in H1 2027; no new safety signals were observed. 12-OCT-2026 08:28 AM ET